scholarly journals The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?

2015 ◽  
Vol 2015 ◽  
pp. 1-28 ◽  
Author(s):  
Ricardo Godinho ◽  
Cristina Mega ◽  
Edite Teixeira-de-Lemos ◽  
Eugénia Carvalho ◽  
Frederico Teixeira ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Therapeutic Potential ◽  
Dipeptidyl Peptidase ◽  
Cardiovascular Complications ◽  
Minimal Risk ◽  
Dipeptidyl Peptidase 4 ◽  
Good Glycaemic Control ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Glucagon Like Peptide 1

Incretin-based therapies, the most recent therapeutic options for type 2 diabetes mellitus (T2DM) management, can modify various elements of the disease, including hypersecretion of glucagon, abnormal gastric emptying, postprandial hyperglycaemia, and, possibly, pancreaticβcell dysfunction. Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) increase glucagon-like peptide-1 (GLP-1) availability and correct the “incretin defect” seen in T2DM patients. Clinical studies have shown good glycaemic control with minimal risk of hypoglycaemia or any other adverse effects, despite the reports of pancreatitis, whose association remains to be proved. Recent studies have been focusing on the putative ability of DPP-4 inhibitors to preserve pancreas function, in particular due to the inhibition of apoptotic pathways and stimulation ofβcell proliferation. In addition, other cytoprotective effects on other organs/tissues that are involved in serious T2DM complications, including the heart, kidney, and retina, have been increasingly reported. This review outlines the therapeutic potential of DPP-4 inhibitors for the treatment of T2DM, focusing on their main features, clinical applications, and risks, and discusses the major challenges for the future, in particular the possibility of becoming the preferred therapy for T2DM due to their ability to modify the natural history of the disease and ameliorate nephropathy, retinopathy, and cardiovascular complications.

scholarly journals Study the effect of Dipeptidyl Peptidase 4 Inhibitors as an Antidiabetic in Type 2 Diabetes Mellitus (T2DM)

2021 ◽  
Vol 11 (5) ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dpp Iv ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Dipeptidyl peptidase IV is a key regulator of insulin- stimulating hormones, glucagon-like peptide and glucose dependent insulinotrophic polypeptide. Thus it is a promising target for treatment of type 2 Diabetes mellitus. Inhibition of plasma Dipeptidyl peptidase IV enzyme lead to enhanced endogenous glucagon like peptide-1, GIP activity which ultimately results in the potentiating of insulin secretion by pancreatic cell and subsequent lowering blood glucose level, HbA [1c], glucose secretion, liver glucose production. One of the principal goals of diabetes management is to attain haemoglobin HbA [1c] treatment goals and prevent the onset or decrease the rate of occurrence of Microvascular conditions.2, 6 numerous treatment options are available for management of Type 2 Diabetes mellitus, various class of DPP IV inhibitor being explored such as Sitagliptin and Vildagliptin successfully launched. Several other novel DPP IV inhibitors are in pipeline, Unless there are clear contraindications, metformin monotherapy is prescribed, and if HbA [1c] targets are not attained after 3 months, 1 of several classes of agents could be added, such as sulfonylurea’s, Thiazolidinediones, dipeptidyl peptidase-4 inhibitors, - glucagon like peptide-1 receptor agonists, or basal insulin.2,6 Despite the broad range of therapeutic options, the attainment of HbA [1c] goals among patients with diabetes remains challenging, with just slightly more than half (52%) of diabetes patients attaining the common HbA [1c] goal of < 7.0%. The present review summarizes latest preclinical and clinical trial data of different DPP IV inhibitors with a special emphasis on their DPP8/9 fold selectivity and therapeutic advantages over GLP-1 based approach. Keywords: Diabetes 2, Dipeptidyl Peptidase-4, glucose-dependent insulinot

Comparison of amylase and lipase levels of patients with Type 2 diabetes under different treatment modalities

2021 ◽  
Author(s):  
Ramazan Cakmak ◽  
Ozge T Caklili ◽  
Sakin Tekin ◽  
Hulya Hacisahinogullari ◽  
Seher Tanrikulu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Basal Insulin ◽  
Dipeptidyl Peptidase ◽  
Treatment Modalities ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Insulin Secretagogues ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Aim: Study aims to assess amylase, lipase of patients with Type 2 diabetes under different types of treatments. Materials & methods: Patients’ treatment modalities including insulin, metformin, pioglitazone, sodium-glucose co-transporter-2 inhibitors, insulin secretagogues, dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists were compared. Results: There was no difference in amylase and lipase levels between dipeptidyl peptidase-4 inhibitor users and non-users (p = 0.2, p = 0.3, respectively) and glucagon like peptide-1 analog users and non-users (p = 0.1, p = 0.7, respectively). Patients who use insulin secretagogues had significantly higher amylase, lipase and (77.2 ± 39.8 vs 69.5 ± 33.0, p = 0,038 and 47.2 ± 33.2 vs 39.6 ± 26.8, p = 0.01, respectively) patients on basal insulin had lower amylase levels (69.9 ± 37.7 vs 77.2 ± 33.7, p = 0.014). Conclusion: Incretin-based therapies showed no difference in amylase and lipase levels whereas there was increase with secretagogues and decrease with basal insulin.

scholarly journals Vildagliptin in the Treatment of Type 2 Diabetes Mellitus

2013 ◽  
Vol 20 (2) ◽  
pp. 165-176
Author(s):  
Ariel Florenţiu ◽  
Radu Lichiardopol
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Important Place ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Type 2 Diabetes Treatment ◽  
Glucagon Like Peptide 1 ◽  
Current Guidelines

Abstract Novel therapeutic approaches are continuously being researched in type 2 diabetes. The incretin class of anti-diabetic agents, consisting of glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors, has already found an important place in the current guidelines. Vildagliptin is a potent dipeptidyl peptidase-4 inhibitor, with numerous trials in type 2 diabetes treatment, both in monotherapy and in combination therapy. This review focuses on vildagliptin pharmacological properties, clinical efficacy and safety, and pharmacoeconomic data.

Sign in / Sign up

Export Citation Format

Share Document